What is BriaCell Therapeutics Corp. Warrant's earnings per share (EPS)?

BriaCell Therapeutics Corp. Warrant (BCTXW) reported diluted earnings per share of -$62.19 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

BriaCell Therapeutics Corp. Warrant (BCTXW) Financials

BCTXW

FY2025 annual

Revenue Not reported for FY2025

Net Income -$26.3M -449.1% YoY

EPS (Diluted) -$62.19 YoY not available

Operating Cash Flow -$28.2M -16.8% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jan 31, 2026 Reported Mar 10, 2026 Currency USD FYE July

Newest figures come from the 10-Q for Q2 FY2026, filed Mar 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BCTXW SEC filings page.

This page shows BriaCell Therapeutics Corp. Warrant (BCTXW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial health score not available

BriaCell Therapeutics Corp. Warrant does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

BriaCell Therapeutics Corp. Warrant passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). No profitability signals pass, all 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

BriaCell Therapeutics Corp. Warrant reported a net loss of $26.3M while operations used $28.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

BriaCell Therapeutics Corp. Warrant reported an operating loss of $27.2M against $37K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income

-$7.2M

YoY-14.8%

QoQ+11.9%

BriaCell Therapeutics Corp. Warrant reported -$7.2M in net income in Q2 2026. This represents a decrease of 14.8% from the same quarter a year earlier. Against the prior quarter it is up 11.9%.

EPS (Diluted)

-$2.58

QoQ+40.7%

BriaCell Therapeutics Corp. Warrant earned -$2.58 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 40.7%.

Revenue

Not reported for Q2 2026.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$29.9M

YoY+496.4%

QoQ+1001.8%

BriaCell Therapeutics Corp. Warrant held $29.9M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

QoQ0.0%

BriaCell Therapeutics Corp. Warrant had 2M shares outstanding in Q2 2026. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-23.9%

YoY+171.1pp

QoQ+63.8pp

BriaCell Therapeutics Corp. Warrant's ROE was -23.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 171.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 63.8 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$6.1M

YoY+6.5%

QoQ-9.4%

BriaCell Therapeutics Corp. Warrant invested $6.1M in research and development in Q2 2026. This represents an increase of 6.5% from the same quarter a year earlier. Against the prior quarter it is down 9.4%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

BCTXW Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BCTXW quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY23	FY22	FY21
R&D Expenses	N/A	$21.3M-21.7%	$27.2M+77.2%	$15.3M+91.2%	$8.0M+296.9%	$2.0M
SG&A Expenses	N/A	$5.9M-3.5%	$6.2M-22.5%	$7.9M+9.2%	$7.3M+46.7%	$5.0M
Operating Income	N/A	-$27.2M+18.4%	-$33.3M-43.2%	-$23.3M-52.2%	-$15.3M-119.2%	-$7.0M
EBITDA	N/A	-$27.1M+18.5%	-$33.2M	N/A	-$15.3M-119.4%	-$7.0M
Interest Expense	N/A	$37K	N/A	N/A	$979-98.8%	$79K
Income Tax	N/A	N/A	N/A	N/A	$0	$0
Net Income	N/A	-$26.3M-449.1%	-$4.8M+76.4%	-$20.3M+24.4%	-$26.8M-94.3%	-$13.8M
EPS (Basic)	N/A	-$62.19-42.4%	-$43.68-3260.0%	-$1.30+24.9%	-$1.73+43.5%	-$3.06
EPS (Diluted)	—	-$62.19	-$43.68	-$1.30+24.9%	-$1.73	N/A
Diluted Shares (Avg)	N/A	423,114	109,699	16M+0.8%	15M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'25	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'24
R&D Expenses	$6.1M+6.5%	$6.7M+82.3%	N/A	$4.8M-37.2%	$5.7M-31.2%	$3.7M-46.5%	N/A	$7.7M+98.4%
SG&A Expenses	$1.5M-0.5%	$1.6M+10.2%	N/A	$1.5M-3.4%	$1.5M-5.6%	$1.5M-9.6%	N/A	$1.6M-13.5%
Operating Income	-$7.5M-5.0%	-$8.3M-61.5%	N/A	-$6.3M+31.4%	-$7.2M+27.1%	-$5.2M+39.4%	N/A	-$9.2M-62.6%
EBITDA	N/A	-$8.3M-61.8%	N/A	N/A	N/A	-$5.1M+39.6%	N/A	N/A
Interest Expense	N/A	N/A	N/A	$37K	N/A	N/A	N/A	N/A
Net Income	-$7.2M-14.8%	-$8.2M-41.3%	N/A	-$6.1M-457.1%	-$6.3M+44.3%	-$5.8M-196.7%	N/A	$1.7M+135.0%
EPS (Basic)	-$2.58+88.9%	-$4.35+86.7%	N/A	-$1.64-201.9%	-$23.31-119.1%	-$32.67-8697.4%	N/A	$1.61+603.1%
EPS (Diluted)	-$2.58	-$4.35	N/A	-$1.64	-$23.31	-$32.67	N/A	$1.61
Diluted Shares (Avg)	3M	2M	N/A	4M	269,957	177,606	N/A	1M

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.

BCTXW Balance Sheet

BCTXW quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY23	FY22	FY21
Total Assets	$13.1M+25.5%	$10.4M-44.1%	$18.6M-51.6%	$38.5M-33.8%	$58.0M
Current Assets	$11.3M+38.1%	$8.2M-55.4%	$18.4M-51.8%	$38.2M-33.9%	$57.8M
Cash & Equivalents	$2.7M-53.1%	$5.8M-57.6%	$13.6M-63.6%	$37.5M-34.6%	$57.3M
Short-Term Investments	$7.4M	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	$21K-27.9%	$30K+136.2%	$13K
Total Liabilities	$3.7M-44.4%	$6.7M-58.4%	$16.1M-42.7%	$28.1M-50.2%	$56.5M
Current Liabilities	$3.3M-33.5%	$5.0M+376.7%	$1.0M+7.4%	$974K+74.9%	$557K
Non-Current Liabilities	$407K-76.2%	$1.7M-88.6%	$15.1M-44.5%	$27.1M-9.0%	$29.8M
Total Equity	$9.4M+151.8%	$3.7M+47.6%	$2.5M-75.7%	$10.3M+552.5%	$1.6M
Retained Earnings	-$120.0M-31.5%	-$91.2M-22.2%	-$74.7M-21.5%	-$61.5M-110.9%	-$29.1M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'25	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'24
Total Assets	$33.6M+258.8%	$13.1M+25.5%	$21.6M+268.7%	$17.0M+174.1%	$9.4M-23.4%	$10.4M-44.1%	$5.9M-78.4%	$6.2M-79.1%
Current Assets	$32.2M+349.3%	$11.3M+38.1%	$19.9M+445.4%	$14.8M+167.4%	$7.2M-39.0%	$8.2M-55.4%	$3.7M-86.4%	$5.5M-81.3%
Cash & Equivalents	$29.9M+496.4%	$2.7M-53.1%	$10.5M+1117.3%	$12.5M+1231.7%	$5.0M-19.7%	$5.8M-57.6%	$862K-95.9%	$936K-96.7%
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$15K+2.3%
Total Liabilities	$3.4M-44.9%	$3.7M-44.4%	$4.3M-49.6%	$5.1M-59.3%	$6.1M-70.1%	$6.7M-58.4%	$8.6M-72.3%	$12.4M-65.1%
Current Liabilities	$3.2M-39.1%	$3.3M-33.5%	$4.0M-46.7%	$4.3M-35.9%	$5.2M+33.3%	$5.0M+376.7%	$7.5M+314.2%	$6.8M+388.6%
Non-Current Liabilities	$195K-78.5%	$407K-76.2%	$338K-69.2%	$730K-87.1%	$906K-94.6%	$1.7M-88.6%	$1.1M-96.2%	$5.7M-83.4%
Total Equity	$30.2M+836.3%	$9.4M+151.8%	$17.3M+745.6%	$11.9M+291.6%	$3.2M+138.8%	$3.7M+47.6%	-$2.7M+28.9%	-$6.2M-5.8%
Retained Earnings	-$127.2M-30.4%	-$120.0M-31.5%	-$111.8M-30.8%	-$103.7M-23.1%	-$97.5M-13.5%	-$91.2M-22.2%	-$85.4M-5.9%	-$84.2M-7.7%

Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Long-Term Investments, Goodwill, Long-Term Debt.

BCTXW Cash Flow Statement

BCTXW quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY23	FY22	FY21
Operating Cash Flow	-$31.0M	-$28.2M-16.8%	-$24.1M-1.6%	-$23.7M-90.2%	-$12.5M-61.1%	-$7.8M
Depreciation & Amortization	N/A	$107K+27.1%	$84K	N/A	$15K+0.1%	$15K
Stock-Based Compensation	N/A	$777K-56.9%	$1.8M-17.8%	$2.2M-28.6%	$3.1M+56.2%	$2.0M
Capital Expenditures	N/A	N/A	$457K	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	-$24.6M	N/A	N/A	N/A
Investing Cash Flow	-$289K	-$7.6M-1021.4%	-$682K	N/A	N/A	N/A
Financing Cash Flow	N/A	$45.4M+928.5%	$4.4M+11.7%	$4.0M+205.7%	-$3.7M-105.8%	$65.0M
Share Buybacks	N/A	N/A	N/A	$47K-99.5%	$10.2M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'25	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'24
Operating Cash Flow	-$8.0M-34.6%	-$7.7M-10.8%	-$8.1M-101.5%	-$7.2M-40.9%	-$5.9M+20.0%	-$7.0M+8.5%	-$4.0M+63.0%	-$5.1M+4.6%
Depreciation & Amortization	N/A	$23K0.0%	N/A	N/A	N/A	$23K+498.2%	N/A	N/A
Stock-Based Compensation	$286K+0.3%	$295K+10.4%	N/A	$225K-42.7%	$285K-43.0%	$267K-50.0%	N/A	$392K+39.5%
Investing Cash Flow	$7.3M+9810.0%	-$75K0.0%	-$7.4M-1518.0%	-$105K	-$75K	-$75K	-$457K	N/A
Financing Cash Flow	N/A	N/A	$13.6M	$14.7M	$5.2M	$12.0M	N/A	N/A

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

BCTXW Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BCTXW quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY23	FY22	FY21
Return on Equity	-281.4%-152.3pp	-129.1%+677.8pp	-806.8%-547.1pp	-259.7%+612.6pp	-872.4%
Return on Assets	-201.2%-155.2pp	-46.0%+63.0pp	-109.0%-39.2pp	-69.8%-46.0pp	-23.8%
Current Ratio	3.42+1.8x	1.65-15.9x	17.59-21.7x	39.24-64.6x	103.81
Debt-to-Equity	0.40-1.4x	1.80-4.6x	6.40+3.7x	2.72-32.9x	35.65

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'25	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'24
Return on Equity	-23.9%+171.1pp	-87.7%+68.6pp	N/A	-51.3%	-195.0%	-156.3%-394.8pp	N/A	N/A
Return on Assets	-21.5%+45.7pp	-62.7%-7.0pp	N/A	-36.0%-63.7pp	-67.2%+25.1pp	-55.7%-87.9pp	N/A	27.7%+44.1pp
Current Ratio	10.10+8.7x	3.42+1.8x	5.01+4.5x	3.41+2.6x	1.37-1.6x	1.65-15.9x	0.49-14.5x	0.82-20.5x
Debt-to-Equity	0.11-1.8x	0.40-1.4x	0.25	0.42	1.90	1.80-4.6x	N/A	N/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
BriaCell Therapeutics Corp. Warrant BCTXW	FY2025	N/A	-$26.3M	N/A	N/A	—
Estrella Immunopharma, Inc. Warrant ESLAW	FY2025	N/A	-$13.1M	N/A	N/A	—
Celularity Inc. Warrant CELUW	FY2025	$26.6M	-$91.7M	N/A	N/A	50/100
GeoVax Labs, Inc. Warrants GOVXW	FY2025	$2.5M	-$21.5M	N/A	N/A	51/100
Pasithea Therapeutics Corp. Warrants KTTAW	FY2025	N/A	-$20.4M	N/A	N/A	—
Lixte Biotechnology Holdings, Inc. Warrants LIXTW	FY2025	N/A	-$6.1M	N/A	N/A	—

Where BriaCell Therapeutics Corp. Warrant Ranks

Frequently Asked Questions

Is BriaCell Therapeutics Corp. Warrant profitable?

No, BriaCell Therapeutics Corp. Warrant (BCTXW) reported a net income of -$26.3M in fiscal year 2025.

What is BriaCell Therapeutics Corp. Warrant's EBITDA?

BriaCell Therapeutics Corp. Warrant (BCTXW) had EBITDA of -$27.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is BriaCell Therapeutics Corp. Warrant's return on equity (ROE)?

BriaCell Therapeutics Corp. Warrant (BCTXW) has a return on equity of -281.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is BriaCell Therapeutics Corp. Warrant's operating cash flow?

BriaCell Therapeutics Corp. Warrant (BCTXW) recorded an outflow of $28.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are BriaCell Therapeutics Corp. Warrant's total assets?

BriaCell Therapeutics Corp. Warrant (BCTXW) had $13.1M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does BriaCell Therapeutics Corp. Warrant spend on research and development?

BriaCell Therapeutics Corp. Warrant (BCTXW) invested $21.3M in research and development during fiscal year 2025.

How many shares does BriaCell Therapeutics Corp. Warrant have outstanding?

BriaCell Therapeutics Corp. Warrant (BCTXW) had 2M shares outstanding as of fiscal year 2025.

What is BriaCell Therapeutics Corp. Warrant's current ratio?

BriaCell Therapeutics Corp. Warrant (BCTXW) had a current ratio of 3.42 as of fiscal year 2025, which is generally considered healthy.

What is BriaCell Therapeutics Corp. Warrant's debt-to-equity ratio?

BriaCell Therapeutics Corp. Warrant (BCTXW) had a debt-to-equity ratio of 0.40 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is BriaCell Therapeutics Corp. Warrant's return on assets (ROA)?

BriaCell Therapeutics Corp. Warrant (BCTXW) had a return on assets of -201.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is BriaCell Therapeutics Corp. Warrant's Piotroski F-Score?

BriaCell Therapeutics Corp. Warrant (BCTXW) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are BriaCell Therapeutics Corp. Warrant's earnings high quality?

BriaCell Therapeutics Corp. Warrant (BCTXW) reported a net loss of $26.3M while operations used $28.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can BriaCell Therapeutics Corp. Warrant cover its interest payments?

BriaCell Therapeutics Corp. Warrant (BCTXW) reported an operating loss of $27.2M against $37K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.